Direct Healthcare Costs Of Diabetes Mellitus Patients In Spain
AbstractObjectives. To estimate the healthcare resources spent by diabetic patients in Spain during the year 2002. Methods. The present work is a cost-of-illness study. Direct healthcare costs were estimated using rates of DM, based on primary and secondary sources of information. A range of prevalence from 5% to 6% of the adult population was determined. The total cost was composed of six items: insulin and oral hypoglycemic agents; other drugs; disposable and consumable goods (glucose test strips, needles and syringes); hospitalization; primary care visits; visits to specialists. Results. The estimated direct cost of DM during the year 2002 ranges from € 2.4 billion to € 2.67 billion. Hospital costs had the highest weight (€ 933 million) in the total, followed by non-insulin, non-hypoglycemic-agent drugs (€ 777-932 million). Much lower are the costs of insulin and oral hypoglycemic agents (€ 311 million), primary care visits (€ 181-272 million), specialized visits (€ 127-145 million) and disposable elements (€ 70-81 million). The per-diabetic, per-year cost ranges between € 1,290 to € 1,476. Discussion. Despite our rather conservative approach to the issue, our findings demonstrate the high direct healthcare costs of diabetic patients. Likewise, they illustrate the magnitude of the costs of treatment of DM-related complications.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by Universidad Carlos III, Departamento de Economía in its series Economics Working Papers with number we036827.
Date of creation: Nov 2003
Date of revision:
This paper has been announced in the following NEP Reports:
- NEP-ALL-2003-12-07 (All new papers)
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Arran Shearer & Adrian Bagust & F. Ampudia-Blasco & Belén Martínez-Lage Álvarez & Isabel Pérez Escolano & Gonzalo París, 2006. "Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain," PharmacoEconomics, Springer, Springer, vol. 24(1), pages 49-59, November.
- Ebere Akobundu & Jing Ju & Lisa Blatt & C. Mullins, 2006. "Cost-of-Illness Studies," PharmacoEconomics, Springer, Springer, vol. 24(9), pages 869-890, September.
- Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González, 2006. "The costs of schizophrenia in Spain," The European Journal of Health Economics, Springer, Springer, vol. 7(3), pages 179-184, September.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: () The email address of this maintainer does not seem to be valid anymore. Please ask to update the entry or send us the correct address.
If references are entirely missing, you can add them using this form.